MELBOURNE, April 25, 2026, 06:06 AEST
- CSL ended Friday at A$130, holding just above its session trough of A$127.75.
- CSL Seqirus is facing renewed attention after the U.S. military changed its flu-shot policy.
- CSL disclosed a A$13.1 million share buyback dated April 23 in its most recent filing.
CSL Limited shares found some footing Friday, though the Australian biotech still hovered near a nine-year trough. Confidence in its Seqirus vaccine division took a blow after a shift in U.S. military flu-vaccine policy. Shares closed at A$130, up 0.8%, having hit A$127.75 earlier in the day.
It matters now: the Pentagon’s move to make flu shots optional for both active and reserve troops, as well as civilians, has shaken a channel investors once counted on for steady demand. Speaking on the change, Defense Secretary Pete Hegseth told troops the vaccine remains available, but “we will not force you.” U.S. Department of War
This latest blow couldn’t have come at a worse time for CSL. The company’s still digging out from earnings downgrades, disappointing U.S. flu shot uptake, and ongoing doubts about its direction. Marc Jocum, senior product and investment strategist at GlobalXETFs, described the Pentagon’s move as “the straw that finally breaks the camel’s back.” Vantage Markets analyst Hebe Chen, meanwhile, flagged a “lack of clarity” around the business, saying CSL hasn’t “convincingly” set a floor for itself. Reuters
CSL kept snapping up its own stock as prices slid. On April 23, the company picked up 101,810 shares for A$13.1 million, according to an ASX filing lodged the next day. That purchase followed 5.9 million shares already bought earlier; CSL’s on-market buyback program could reach as much as US$750 million.
The buyback’s just part of CSL’s broader fix. Back in February, the company posted first-half revenue of US$8.3 billion, marking a 4% drop, and underlying NPATA came in at US$1.9 billion, down 7%. “We are clearly not satisfied,” Chief Financial Officer Ken Lim said. CSL left its fiscal 2026 outlook unchanged, still targeting 2%-3% revenue growth and 4%-7% NPATA growth at constant currency.
Seqirus makes a significant contribution. According to CSL’s 2025 annual report, Seqirus posted revenue of US$2.17 billion. That’s compared with US$11.16 billion at CSL Behring, and US$2.23 billion at CSL Vifor. The report also pointed to lower immunisation rates after the pandemic, with the drop most noticeable in the U.S. For fiscal 2025, the U.S. remained CSL’s top market, generating US$7.31 billion in revenue.
Competition keeps shifting. Last July, GSK, CSL Seqirus, and Sanofi kicked off U.S. shipments for the 2025-26 flu season. CSL’s lineup—Flucelvax, Fluad, and Afluria—now targets the same buyers as its heavyweight vaccine rivals, all with diverse drug businesses.
But that doesn’t mean the risk is locked in. The Pentagon’s move stops short of an outright flu vaccine ban, and CDC guidance hasn’t changed—annual flu shots remain the top recommendation for everyone six months and up. Vaccine makers were still anticipating up to 154 million flu doses would be available in the U.S. for the 2025-26 season.
CSL faces a risk if voluntary military demand slips and U.S. civilian immunisation doesn’t pick up. In that scenario, Seqirus would be left more exposed, right when investors are focused on margin durability, market share defense, and any possible separation or valuation shift for the business.
Right now, it’s credibility—not vaccine tech—that’s drawing the spotlight. CSL wants investors on board with its cost-cutting moves, its guidance, its buyback plan. But a sudden U.S. policy move has thrown fresh uncertainty over demand in one of the company’s headline businesses.
